Decentralized Clinical Trials (DCTs) have increased in popularity during the pandemic. DCTs tout better patient participation, lower dropout rates, and more diverse patient pools. But as the world opens up and traditional clinical trial capacity returns to pre-pandemic levels, will DCTs maintain their popularity? Join industry experts from Bristol Myers Squibb (BMS) and Thread(R) as they discuss the merits and future of DCTs.